In vitro diagnosis of tumor and/or inflammatory pathologies

Technology description

The Nicotinic acid phosphoribosyltransferase (NAPRT) Bio-plex/Luminex assay is used for the in vitro quantitative determination of human NAPRT in biological fluids, including culture supernatants and serum or plasma. A very similar enzyme, nicotinamide phosphoribosyltransferase (NAMPT), is present in the extracellular space, and its levels increase in inflammatory/metabolic conditions, including in cancer. Because NAMPT is structurally and functionally related to the NAPRT enzyme, then the inventors have hypothesized a possible role in the extracellular space also for the NAPRT.
An ad hoc commercial NAMPT enzyme-linked immunosorbent assay (ELISA) can be used to evaluate extracellular NAMPT concentrations. On the contrary, nothing is known about the presence of NAPRT in the extracellular space, and there are no commercially available assays to determine extracellular NAPRT levels. This assay was therefore set up to quantify NAPRT levels in human plasma/serum or in culture supernatants. To do so, we exploited luminex technology and commercially available monoclonal and polyclonal antibodies. Commercially available recombinant proteins were used to build a titration curve. The assay is for research only, is ready to use and is very sensitive.

  • In vitro monitoring of NAPRT release in culture supernatants
  • Functional studies in vitro/in vivo
  • Determination of NAPRT levels in plasma/serum from inflammatory/metabolic disease patients
  • Determination of NAPRT levels in plasma/serum from cancer patients
Key advantages
  • Quantitative determination of NAPRT in all biological fluids
  • High-specificity and sensibility
  • Very little volume of sample required
  • Reproducibility of results
  • No cross-reactivity with NAMPT
Filing date and application number

Filing date: 20/02/2018

Application number: 102018000002866



  • Università degli Studi di Torino
  •  Italian Institute for Genomic Medicine (IIGM)